Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouattour, Mohamed, Raymond, Eric, Qin, Shukui, Cheng, Ann‐Lii, Stammberger, Uz, Locatelli, Giuseppe, Faivre, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Concise Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873445/
https://www.ncbi.nlm.nih.gov/pubmed/28862760
http://dx.doi.org/10.1002/hep.29496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873445/
https://www.ncbi.nlm.nih.gov/pubmed/28862760
http://dx.doi.org/10.1002/hep.29496

Ejemplares similares